Navigation Links
Gene Mutation Suggests New Treatment Target for Specific Lymphoma

WEDNESDAY, Dec. 22 (HealthDay News) -- Researchers have identified a gene mutation that may offer a target for new treatments for a type of lymphoma.

The team found that a mutation of the MYD88 gene is one of the most frequent genetic abnormalities in patients with this cancer, known as large B cell lymphoma.

The MYD88 gene encodes a protein that is crucial for normal immune response to invading microorganisms. The mutation identified in this study can cause uncontrolled cellular signaling, resulting in the survival of malignant cells.

A subgroup of the large B cell lymphoma that has a dismally low cure rate -- known as the activated B cell-like (ABC) subtype -- appears particularly susceptible to the gene.

Lymphoma is a cancer of the blood that starts in white blood cells. Diffuse large B cell lymphoma, in turn, is a type of non-Hodgkin lymphoma, in which white blood cells known as lymphocytes multiply out of control. There are three subtypes of diffuse large cell lymphoma: Patients with the ABC form have the lowest rate of three-year survival, with only 40 percent reaching that milestone.

The researchers, led by scientists at the U.S. National Cancer Institute (NCI), found that the mutant form of MYD88 allowed the ABC lymphoma cells to survive but the non-mutated version did not.

One more piece of the puzzle was unraveled through another cell-signalling protein called IRAK4. The researchers found it functioned as an enzyme to modify a substance called IRAK1, which was required for the mutant MYD88 protein to promote lymphoma cell survival.

"We believe the results of this study may provide a method to identify patients with the [ABC subtype] whose tumors may depend upon MYD88 signaling," study author Louis M. Staudt, of NCI's Center for Cancer Research, said in an NCI news release.

These patients, he said, may thus benefit from therapies targeting "regulatory pathways that sustain the survival of these lymphoma cells."

The study appears online Dec. 22 in the journal Nature.

More information

The American Cancer Society has more about non-Hodgkin lymphoma.

-- Robert Preidt

SOURCE: U.S. National Cancer Institute, news release, Dec. 22, 2010

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Single gene mutation induces endometrial cancer
2. Genetic Mutation Linked to Prostate Cancer in Blacks
3. Gene Mutations Identified for Charcot-Marie-Tooth Syndrome
4. Study shows that mutations in 1 gene cause many cancers
5. Parkinsons Linked to Genetic Mutation
6. Breast cancer patients with BRCA mutations 4 times more likely to get cancer in opposite breast
7. Gene Mutations Up Risk for Cancer in Opposite Breast
8. Gene Mutation Ups Risk of Sudden Death in People with Epilepsy
9. Heart Disease Among Childhood Cancer Survivors Tied to Gene Mutations
10. New research indicates that DNA sequence itself influences mutation rate
11. Single Lung Tumor Contains 50,000 Mutations
Post Your Comments:
Related Image:
Gene Mutation Suggests New Treatment Target for Specific Lymphoma
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... The Visiting ... Day Market. Featuring a collection of specialty vendors and unique items from across the ... and quality-focused health and wellness services offered by the VNA. The boutique will ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Software Development, has been awarded a contract by the Center for Medicare and ... aims to accelerate the enterprise use of Agile methodologies in a consistent and ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest and ... plans to open a flagship location in Covington, LA at 401 N. U.S. Highway ... store next to Office Depot in the Holiday Square shopping center. Its location allows ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: ... develop to enable prevention of a major side effect of chemotherapy in children. ... pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a dose ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... one of Michigan’s 2017 Best and Brightest in Wellness® by Best and Brightest. ... awards program on Friday, Oct. 20 from 7:30 a.m. to 2 p.m. at ...
Breaking Medicine News(10 mins):
(Date:9/19/2017)... -- HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy ... team developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D ...
(Date:9/18/2017)... , Sept. 18, 2017 EpiVax, ... of bioinformatics and immune engineering, today announced ... influenza A (H7N9) vaccine. ... to seasonal influenza and presents a challenge ... prior exposure to be effective. Using state-of-the-art ...
(Date:9/12/2017)... 12, 2017  Consumer reviews on the independent review site ... number one company for hearing aids, ranking it higher than ... ... by Consumers For Hearing Aids ... is an online store that provides high performance, state-of-the-art, German-engineered hearing ...
Breaking Medicine Technology: